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Rett syndrome (RTT) is a severe neurodevelopmental disorder typically arising from
spontaneous mutations in the X-chromosomal methyl-CpG binding protein 2 (MECP2)
gene. The almost exclusively female Rett patients show an apparently normal
development during their first 6–18 months of life. Subsequently, cognitive- and motor-
impairment, hand stereotypies, loss of learned skills, epilepsy and irregular breathing
manifest. Early mitochondrial impairment and oxidative challenge are considered to
facilitate disease progression. Along this line, we recently confirmed in vitro that
acute treatment with the vitamin E-derivative Trolox dampens neuronal hyperexcitability,
reinstates synaptic plasticity, ameliorates cellular redox balance and improves hypoxia
tolerance in male MeCP2-deficient (Mecp2−/y) mouse hippocampus. Pursuing these
promising findings, we performed a preclinical study to define the merit of systemic
Trolox administration. Blinded, placebo-controlled in vivo treatment of male mice started
at postnatal day (PD) 10–11 and continued for ∼40 days. Compounds (vehicle only,
10 mg/kg or 40 mg/kg Trolox) were injected intraperitoneally every 48 h. Detailed
phenotyping revealed that in Mecp2−/y mice, blood glucose levels, lipid peroxidation,
synaptic short-term plasticity, hypoxia tolerance and certain forms of environmental
exploration were improved by Trolox. Yet, body weight and size, motor function and the
rate and regularity of breathing did not improve. In conclusion, in vivo Trolox treatment
partially ameliorated a subset of symptoms of the complex Rett phenotype, thereby
confirming a partial merit of the vitamin E-derivative based pharmacotherapy. Yet, it also
became evident that frequent animal handling and the route of drug administration are
critical issues to be optimized in future trials.
Keywords: redox signaling, oxidative stress, reactive oxygen species (ROS), Rett syndrome, antioxidants,
preclinical study, disease progression, pharmacotherapy
INTRODUCTION
Rett syndrome (RTT) is a progressive neurodevelopmental disorder that almost exclusively
affects girls with an incidence of ∼1/10,000 live female births (Rett, 1966; Hagberg,
1985; Chahrour and Zoghbi, 2007). Spontaneous mutations in the X-chromosomal
methyl-CpG binding protein 2 gene (MECP2) are present in 95% of classic Rett patients
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(Amir et al., 1999; Shahbazian and Zoghbi, 2001). RTT
is characterized by an apparently normal development for
the first 6–18 months of life. This is then followed by
a gradual appearance of mental, neurological and physical
symptoms. Rett girls often show autism-like behaviors, severe
mental impairment, slowed growth, motor dysfunction and
seizures. Other symptoms include cardiac abnormalities and
pronounced breathing disturbances (Shahbazian and Zoghbi,
2001). Especially the awake state is characterized by phases of
irregular breathing with apneas and associated transient drops in
arterial O2 saturation (Julu et al., 2001; Stettner et al., 2008).
Mitochondrial alterations contribute to cellular redox
imbalance, and are therefore expected to be involved in the
pathogenesis of RTT (De Felice et al., 2012b; Müller and Can,
2014; Filosa et al., 2015). Typical morphological changes of these
organelles include a swollen appearance with vacuolization,
granular inclusions and membranous changes, and they were
detected in biopsy material obtained from Rett patients as
well as Rett mice (Eeg-Olofsson et al., 1990; Dotti et al., 1993;
Belichenko et al., 2009). Furthermore, expression of certain
subunits of respiratory complexes I and III seems to be indirectly
controlled by MeCP2 (Kriaucionis et al., 2006), and just recently
it has been shown that the mitochondrial overproduction of
H2O2 in Rett mice is mainly due to an aberrant activity of
complex II (De Filippis et al., 2015). Interestingly, oxidative
stress does not only occur in MeCP2 deficiency but also in
MECP2 duplication syndrome (Signorini et al., 2016). In view of
the irregular breathing and the resulting frequent intermittent
hypoxic episodes in RTT, it is reasonable to assume that
such transiently reduced O2 supply may further aggravate the
conditions of already disturbed mitochondria and cellular redox
imbalance.
Various oxidative stress markers—such as non-protein-
bound iron, protein carbonyls, malondialdehyde (MDA) and
F2-isoprostanes—are increased in blood samples of Rett patients
(Sierra et al., 2001; De Felice et al., 2009, 2011, 2012b). These
blood analyses also revealed a reduced activity of the pivotal
scavenging enzyme superoxide dismutase (Sierra et al., 2001)
as well as decreased vitamin E levels (Formichi et al., 1998).
Recently, we confirmed an increased oxidative burden and
mitochondrial dysfunction also in hippocampal tissue of male
MeCP2-deficient (Mecp2−/y) mice (Großer et al., 2012), by
taking advantage of genetically-encoded optical redox indicators
which allow to quantify redox conditions and dynamics (Hanson
et al., 2004; Funke et al., 2011). Interestingly, these redox-
and mitochondrial alterations in MeCP2-deficient brains already
start to manifest at the neonatal stage, i.e., long before erratic
breathing and other characteristic Rett symptoms are evident.
Therefore, increased reactive oxygen species (ROS) levels and
downstream redox changes are considered pivotal elements
driving the pathogenesis of RTT (Sierra et al., 2001; De Felice
et al., 2009; Großer et al., 2012; Müller and Can, 2014).
The pathogenic potential arising from redox alterations may
not necessarily be linked to tissue damage only. Since the activity
and function of various ion channels and neurotransmitter
receptors is closely controlled by ambient redox conditions
(Aizenman et al., 1989; Hammarström and Gage, 2000; Müller
and Bittner, 2002; Sah et al., 2002; Hidalgo et al., 2004), any
transient or sustained redox imbalance may easily contribute
to the disturbed function of excitatory and inhibitory synapses
(Blue et al., 1999; Dani et al., 2005; Medrihan et al., 2008), the
impaired synaptic plasticity (Asaka et al., 2006; Moretti et al.,
2006), and the neuronal hyperexcitability (Zhang et al., 2008;
Calfa et al., 2011) which are closely linked to MeCP2-deficiency.
These redox-mediated changes may be transient or persisting,
result from too oxidizing or too reducing conditions, and they
can be expected to occur way before any oxidative tissue damage
is manifesting.
In view of the mitochondrial dysfunction, the associated
oxidative stress and their assumed role for the pathogenesis
of RTT, improving mitochondrial function and/or reinstating
cellular redox balance appear to be promising treatment concepts
in RTT. Indeed, supplementation with ω-3 polyunsaturated
fatty acids (PUFAs) successfully reduced the levels of several
oxidative stress biomarkers in the blood of Rett patients and
ameliorated some of the typical Rett symptoms (De Felice et al.,
2012a; Maffei et al., 2014). Along this line, we recently evaluated
in vitro the therapeutic merit of the free-radical scavenger
Trolox, a vitamin E-derivative. In acute hippocampal slices of
adult and symptomaticMecp2−/y mice, we confirmed that acute
incubation with Trolox dampens neuronal hyperexcitability,
reinstates synaptic plasticity, ameliorates cellular redox balance
and improves the hypoxia tolerance in Mecp2−/y hippocampus
(Großer et al., 2012; Janc and Müller, 2014).
Based on these promising in vitro findings, we performed
this preclinical trial, to define the merit of chronic Trolox
treatment in vivo. Starting at postnatal day (PD) 10/11, Trolox
was given to wild type (WT) and Mecp2−/y mice every other
day by intraperitoneal (i.p.) injection for ∼40 days. We screened
for possible improvements in systemic and blood parameters,
behavioral aspects and respiration.Markers of protein- and lipid-
oxidation were quantified in isolated brain tissue, and detailed
in vitro analyses on acute brain slices rated synaptic function
and plasticity, hypoxia tolerance and mitochondrial metabolism.
Also, potential changes in brain gross morphology were assessed.
MATERIALS AND METHODS
As mouse model for RTT, we used, as in our earlier studies mice
lacking the Mecp2 gene B6.129P2(C)-Mecp2tm 1.1Bird (Guy et al.,
2001). The entire study was performed on male mice, asMecp2-/y
mice show an earlier and more severe disease onset and present
the more uniform conditions of complete MeCP2 deficiency. All
procedures are in accordance with national German regulations,
and were authorized by the Office of Animal Welfare of the
UniversityMedical Center Göttingen and the Lower Saxony State
Office for Consumer Protection and Food Safety.
Systemic Trolox Treatment
The systemic treatment was designed as blinded, placebo-
controlled study (Figure 1). Mice were randomly assigned to
a treatment group, and starting from PD10–11 they received
either vehicle (phosphate buffered saline, PBS), low-dose Trolox
(10 mg/kg body weight) or high-dose Trolox (40 mg/kg body
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FIGURE 1 | Treatment plan and study design. Mice were randomly
assigned to a treatment (phosphate buffered saline (PBS) only, 10 mg/kg
Trolox, 40 mg/kg Trolox). Injections were started PD10–11, given every 48 h,
and continued up to PD47–50. Mice then underwent behavioral testing before
the final experiment (tissue isolation or transcardial perfusion). The schematic
refers to a single cohort, consisting of at least 20 mice. Six of these cohorts
(three treatment paradigms per genotype) were run in parallel fully blinded,
identified for correct treatment by color codes only. Unblinding was done after
all mice had been treated and all data had been analyzed.
weight). Compounds were administered by i.p. injection every
48 h for a duration of ∼6 weeks, i.e., until the mice had
reached an age at which characteristic Rett symptoms are clearly
evident (∼PD47–50). In case of complications (massive weight
loss, infections, edema, obvious signs of pain or suffering,
tremors, lethargy, ruffled fur, difficulty breathing) treatment
was terminated and the respective mouse euthanized. Injections,
phenotypic analyses, in vitro experiments and data analyses
were team efforts, with some overlap among those performing
injections, running experiments and analyzing data. Everyone
actively involved was blinded with respect to both mouse
genotype and type of treatment. Yet, in view of the severe
phenotype of the Mecp2−/y mice and the differences in body
weight, their genotype becamemore and more obvious once they
reached PD30 and beyond.
Details on the pharmacokinetics of Trolox are not available,
and its high blood brain barrier transferability has been
demonstrated only very recently (Wada et al., 2016). Therefore,
our compound dosing was chosen in accordance to earlier
reports in which Trolox was i.p. injected or orally fed to
rats/gerbils and successfully ameliorated neurotoxic effects as
well as ischemia-related neurodegeneration (Gupta and Sharma,
2006; AlMutairy et al., 2010). At the same time, the higher Trolox
dose of 40 mg/kg is the consequence of the maximum soluble
amount in saline (∼4 mg/ml without additional solvents) and
the maximum allowable volume for i.p. injections in mice. The
48 h injection interval is based on a report on mice, which shows
that upon administration, the levels of the vitamin E compound
tocopherol in blood, brain, lung, kidney and liver remain stable
for at least 24 h upon a single dose administration (Baxter
et al., 2012). Furthermore, we were concerned that i.p. injections
performed on a daily basis for several weeks—especially in view
of the early onset of treatment (PD10/11)—would be too stressful
for the fragile Rett mice.
Solutions
All chemicals and assays were obtained from Sigma-Aldrich,
unless indicated otherwise. Trolox ((±)-6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid) was dissolved in PBS
(1 mg/ml and 4 mg/ml injection solution), stored at 4◦C,
and used within 1 week. Artificial cerebrospinal fluid (ACSF)
required for in vitro experiments contained (in mM): 130 NaCl,
3.5 KCl, 1.25 NaH2PO4, 24 NaHCO3, 1.2 CaCl2, 1.2 MgSO4 and
10 glucose. Constant aeration with carbogen (95% O2, 5% CO2)
adjusted pH to 7.4. Cyanide (CN−) was dissolved as aqueous
1 M stock and stored at −20◦C. FCCP (carbonyl cyanide-
4-(trifluoromethoxy) phenylhydrazone, Tocris Bioscience) and
rhodamine 123 (Rh123) were dissolved as 10 mM stocks in
dimethyl sulfoxide (DMSO) and stored at 4◦C. Final DMSO
concentration was ≤0.02%.
Behavioral Testing and Whole-Body
Plethysmography
For detailed phenotyping, all mice underwent various behavioral
tests prior to final experiments, to rate motor function and
activity, environmental exploration, and working memory.
However, to prevent an ‘‘overtesting’’ not every animal
underwent each test available, but typically only three of
the behavioral tests. Motor coordination was tested on three
consecutive days (∼PD43), using a mouse Rotarod (Ugo Basile).
The first day allowed the mice to adapt to the treadmill, the
second day defined motor performance, and improvement from
the second to the third day represents motor learning. Mice were
placed on the rotating drum (non-skid surface, 30 mm diameter),
the speed continuously accelerated from 5 rpm to 50 rpm within
5 min, and the time each animal stayed on the rod was measured
as latency to fall. Occasionally, mice clasped to the rotating drum
without running. In these cases the timing was stopped after five
full rotations of clasping.
Motor activity and environmental exploration were rated
in open field and hole board tests (∼PD47–50). In the open
field (45 cm × 45 cm), the motility of mice was monitored
for a duration of 5 min. Any lateral movements were detected
by a grid of 16 infrared beams and tracked using ActiTrack
v2.7.13 software (Panlab, Harvard Apparatus). For detailed
analyses, the open field was divided in three zones (a 95 mm
wide periphery, the respective 95 mm × 95 mm corners and
the remaining 260 mm × 260 mm center) which were defined
as a virtual mask in the tracking software (see Figure 3B). In
the hole board configuration, a base-plate with 16 equally spaced
holes (25 mm diameter) was inserted into the arena, and an
additional grid of infrared beams detected the head-dipping
behavior of the mice.
Working memory was analyzed in a Y-maze (32.5 cm long
and 8.5 cm wide arms, equally spaced at 120◦ angles), in which
mice were tracked by video camera and ANY-maze software
(Stoelting). Around PD47–50, mice were placed in the start arm
and allowed to explore the maze for 10 min while one arm
was blocked. After 1 h the test was repeated for a duration
of 5 min with all arms being accessible, and the number of
spontaneous alterations was counted. An alternation is defined
as consecutive entry of all three arms in any order. Thus, the
number of maximum possible alternations is the total sum
of arm entries minus two. To compare mice, the number
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of spontaneous alternations was normalized to the maximum
possible alternations.
To analyze breathing (PD47–50), mice were placed in a
whole-body plethysmograph (Data Sciences International)
and allowed to breathe naturally under conscious and
unrestrained conditions. Breathing patterns were recorded
by Ponemah v5 control software. After a ∼10 min adaptation,
breathing was analyzed for the following 3 min. The individual
respiratory cycles were detected by the threshold crossing
method (Clampfit 10.3, Molecular Devices), and breathing
frequencies calculated as the reciprocal of the averaged
inspiratory interval. The irregularity score was determined
as the normalized difference between a pair of subsequent
breaths (Barthe and Clarac, 1997; Telgkamp et al., 2002;
Wegener et al., 2014).
Preparation and Transcardial Perfusion
To obtain brain tissue, mice (∼PD50) were deeply anesthetized
with ether and decapitated. The brain was isolated and placed
in chilled ACSF for ∼2 min. Coronal brain slices of 400 µm
thickness were cut using a vibroslicer (752M Vibroslice,
Campden Instruments) and split along the sagittal midline.
Depending on the experiment they were transferred to an
interface recording chamber or a submersion-style storage
chamber. Prior to the experiments, slices were left undisturbed
for at least 90 min, to ensure their recovery from dissection
and slicing. Any brain tissue not required for acute analyses
was immediately frozen in liquid nitrogen for later biochemical
assays. Blood samples collected upon decapitation served to
determine hematocrit and blood glucose levels (Contourr blood
glucose meter; Bayer).
For transcardial perfusion, deep ether anesthesia was
confirmed by the absence of foot-pinch reflexes. The chest was
opened, the heart exposed, and an injection needle inserted in the
left ventricle. Remaining blood was removed from the vascular
system by PBS perfusion, then perfusion fixation was performed
by 4% paraformaldehyde (PFA) in PBS. Once isolated, brains
were postfixed for 3 days in 4% PFA and long-term stored in PBS
with 0.02% NaN3.
Nissl Staining
Perfusion-fixed brains were cut into coronal sections (30 µm)
using a microtome (VT1200S Leica). The sections were placed
on microscope slides, passed through a descending ethanol
series (95% for 15 min; 70% and 50% for 1 min each) and
washed twice in demineralized water. They were then stained
in an aqueous cresyl violet/acetate solution (5 mg/ml cresyl
violet, 30 µl/ml acetic acid) for 2 min. Remaining dye was
washed out by water, followed by an ascending ethanol series
(50% for 1 min, 70% plus 1% acetic acid for 2 min, 95% for
2 min, 99.9% for 2 min). Finally, sections were cleared in xylol
(5 min), dried (15 min), and coverslipped with Eukitt quick-
hardening mounting medium. For the morphometric studies a
rostrocaudal location of about −1.7 mm with respect to Bregma
was chosen, and three sections per brain were analyzed using
a digital microscope (Coolscope, Nikon) with NIS-Elements
3.2 cell analysis software. Quantification of neuronal size is
based on soma area, and it was determined by randomly
selecting five cells in each section analyzed. Those cells were
chosen, which showed clearly identifiable boundaries and were
not obstructed by neighboring/overlapping objects. The cross-
sectional area was determined in the best focal plane by
drawing along the outer cell boundaries (NIS-Elements analysis
software).
Electrophysiological Recordings
Electrophysiological recordings were run in an Oslo style
interface chamber, which was constantly aerated with
carbogen (95% O2, 5% CO2; 400 ml/min) and supplied
with oxygenated ACSF (3–4 ml/min). Synaptic plasticity
and hypoxic responses were analyzed at temperatures of
31–32◦C and 35–36◦C, respectively. Recording electrodes were
pulled from borosilicate capillaries (GC150TF-10, Harvard
Apparatus) on a horizontal electrode puller (Model P-97, Sutter
Instruments) and filled with ACSF. Their tip resistance was
trimmed to ∼5 M. Schaffer collaterals were stimulated with
stainless steel electrodes (50 µm diameter microwire, AM-
Systems), delivering 0.1 ms unipolar stimuli (S88 stimulator
with PSIU6 stimulus isolation units, Grass Instruments). Field
excitatory postsynaptic potentials (fEPSPs) and extracellular
DC potentials were recorded in CA1 st. radiatum, using
a locally constructed field potential amplifier (Hepp et al.,
2005). Data were sampled with an Axon Instruments Digitizer
1322A and analyzed by PClamp 9.2 software (both Molecular
Devices). Synaptic function was rated based on input/output
(i/o) curves and long-term potentiation (LTP). For LTP
experiments, stimulus intensity was set to obtain half-maximum
responses. Stable LTP was induced by three subsequent
trains of high-frequency stimulation (100 Hz, 1 s, 5 min
train interval; Janc and Müller, 2014). Hypoxia-induced
spreading depression (HSD) was elicited by switching the
interface chamber’s gas supply to nitrogen (95% N2 and 5%
CO2); O2 was resubmitted 30 s after HSD onset (Hepp et al.,
2005).
Optical Recordings
Mitochondrial metabolism and membrane potentials were
monitored in CA1 st. radiatum using computer-controlled
epifluorescence imaging systems. They were composed of
a polychromatic xenon-light source (Polychrome II, Till
Photonics), a CCD-camera (SensiCam QE, PCO) and an upright
microscope (either Axiotech or Axioskop I, Zeiss). Hippocampal
slices were imaged in a submersion-style chamber (30–33◦C),
using a 40× 0.8NA water immersion objective (Achroplan
Zeiss). FAD and NADH tissue autofluorescence were monitored
in a ratiometric approach (Duchen and Biscoe, 1992), by
alternating excitation at 360 nm (NADH, 70 ms exposure)
and 445 nm (FAD, 40 ms exposure). Image pairs were taken
every 5 s (0.2 Hz frame rate), and autofluorescence was
separated by a 450 nm dichroic mirror and a 510/80 nm
emission bandpass filter (Gerich et al., 2006; Janc and Müller,
2014).
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For Rh123 imaging of mitochondrial membrane potential
changes, slices were dye-loaded (5µM, 15min) in a miniaturized
staining chamber (Funke et al., 2007). As Rh123 was used in
quenching mode, depolarization of mitochondria is indicated by
an increase in Rh123 fluorescence (Emaus et al., 1986; Foster
et al., 2006). Rh123 was excited at 480 nm using frame rates of
0.2 Hz and 5 ms exposure times; its emission was separated using
a 505 nm dichroic mirror and a 535/35 nm bandpass emission
filter.
Lipid Peroxidation and Protein
Carbonylation
To assess oxidative tissue damage, lipid peroxidation and protein
carbonylation were quantified in cryopreserved tissue samples of
frontal cortex. Lipid peroxidation was determined in ∼10 mg
neocortical tissue using a colorimetric assay (MAK085), which
is based on the reaction of MDA with thiobarbituric acid (TBA).
Tissue samples were homogenized on ice in 300 µl MDA lysis
buffer containing butylhydroxytoluene (100×), and debris was
removed by centrifugation (13,000 g, 10 min). Then 0.2 ml of
homogenate was added to 600 µl TBA solution. This mixture
was incubated for 60 min at 95◦C, cooled down on ice to room
temperature (RT), and centrifuged again (13,000 g, 30 s) before
absorbance at 532 nm was determined against a MDA standard
curve.
Protein oxidation was determined using a protein carbonyl
assay (MAK094), which reports the interaction of protein
carbonyl groups with 2,4-dinitrophenylhydrazine (DNPH).
The resulting stable dinitrophenyl (DNP) hydrazone adducts
are detected spectrophotometrically. Tissue samples were
homogenized in 500 µl CelLytic M buffer and incubated for
15 min before debris was removed by centrifugation (14,000 g,
15 min). The supernatant was collected and its protein content
determined by Bradford assay (B6916). To quantify protein
carbonyl levels, 0.15 ml of tissue supernatant (∼10 mg/ml
protein) was mixed with 0.15 ml of DNPH solution and
incubated at RT for 10 min. Then, protein was precipitated by
adding 0.45 ml of 100% trichloroacetic acid (5 min incubation
on ice) and subsequent centrifugation at 13,000 g for 2 min.
The pellet was dissolved in ice-cold acetate, incubated for
5 min at −20◦C and centrifuged again at 13,000 g for 2 min,
before the previous acetate washing step was repeated. Then the
precipitated protein was re-dissolved in 0.33 ml of 6 M guanidine
solution and incubated for 20 min at 60◦C. Samples were allowed
to cool down to RT; their carbonyl content was calculated
from the absorbance at 375 nm, and their final total protein
content determined by bicinchoninic acid assay (BCA1 AND
B9643).
Statistics
For electrophysiological and optical recordings slices of at
least five different brains of each genotype and treatment
group were used. In behavioral experiments at least six mice
per group were tested. All numerical values are given as
mean± standard deviation; the number of experiments (n) refers
to the number of slices or mice analyzed. The significance of
the changes observed was tested by two-way ANOVA followed
by post hoc all-pairwise multiple comparisons (Holm-Sidak
method); statistical calculations were performed with Sigmaplot
12.5 (Systat Software Inc.). In the diagrams, statistically
significant differences among treatment groups of the same
genotype are indicated by asterisks (∗P < 0.05, ∗∗P < 0.01;
∗∗∗P < 0.001), and those among WT and Mecp2−/y mice
are identified by crosshatches (#P < 0.05, ##P < 0.01,
###P < 0.001).
RESULTS
To define the pharmacological merit of a systemic free-radical
scavenger treatment in a mouse model of RTT, we assessed
various systemic and behavioral parameters and conducted an
array of in vitro analyses on the brain tissue of the treated mice.
Systemic Parameters
In vivo treatment started at the presymptomatic stage (PD10–11),
to detect potential differences in disease onset or progression.
Injections of either PBS, low-dose (10 mg/kg) or high-dose
Trolox (40 mg/kg) were performed every 48 h for ∼6 weeks
(Figure 1). In total, 177 mice (88 WT and 89 Mecp2−/y mice)
received blinded Trolox or PBS injections for the entire treatment
duration. Another 17 mice (3 WT, 14 Mecp2−/y) died or had
to be euthanized before the end of treatment. The deceased WT
mice had received 10 mg/kg (n = 2) and 40 mg/kg Trolox (n = 1);
the deceased Mecp2−/y mice belonged to PBS (n = 1), low-dose
Trolox (n = 7) and high-dose Trolox-treated groups (n = 6). For
summary and detailed survival rates see Table 1.
In terms of body weights, WT and Mecp2−/y mice
were indistinguishable up to the third postnatal week. Yet,
from PD22 on, all Mecp2−/y mice—independent of the
treatment—showed a reduced growth and gained less body
weight than the WTs (Figure 2A). Their final body weight at
PD50 was about half the weight of WT mice, and their body
mass index (BMI, determined as body weight divided by body
length2) was also significantly lower (Figure 2B). Genotype-
matched comparison did not reveal any effects of the type of
treatment on the growth parameters among the different WT or
Mecp2−/y groups.
Blood analyses detected ∼29% lower blood glucose levels in
PBS-treated Mecp2−/y mice than in the corresponding WTs.
ThoseMecp2−/y mice receiving low or high Trolox doses, showed
a trend towards higher glucose levels and they did no longer
differ significantly from PBS-treated or Trolox-receiving WTs
(Figure 2C). In contrast, Trolox tended to reduce glucose levels
TABLE 1 | Detailed overview of the six treatment groups, their group sizes
and the relative survival rates reported as % values of total group size.
Treatment Survived Deceased Total
WT PBS only 29 (100%) 0 (0%) 29
10 mg/kg Trolox 24 (92.3%) 2 (7.7%) 26
40 mg/kg Trolox 35 (97.2%) 1 (2.8%) 36
Mecp2−/y PBS only 30 (96.8%) 1 (3.2%) 31
10 mg/kg Trolox 33 (82.5%) 7 (17.5%) 40
40 mg/kg Trolox 26 (81.2%) 6 (18.8%) 32
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FIGURE 2 | Trolox treatment does not improve growth and hematocrit of Mecp2−/y mice, but abolishes the genotypic differences in blood glucose
levels. (A) Body weights of Mecp2−/y and wild type (WT) mice were indistinguishable at first. Yet, from the third postnatal week, all Mecp2−/y groups gained less
weight. Plotted are averaged body weights of 24–35 mice. For clarity, standard deviations are included for the PBS-treated groups only. Crosshatches indicate
significant differences between Mecp2−/y and the respective WT mice (##P < 0.01; ###P < 0.001). (B) The body mass index (BMI) determined at PD47–50 was
significantly lower in Mecp2−/y than in WT mice. Bar shading and patterns also apply to panels (C,D). The respective number of animals analyzed is indicated below
each bar. (C) Mecp2−/y mice receiving PBS showed a lower blood glucose level than PBS-treated WTs. Low- and high-dose Trolox treatment tended to increase
glucose levels in Mecp2−/y mice and abolished the genotypic differences. In WTs, high-dose Trolox significantly reduced the blood glucose content. This
genotype-matched difference is indicated by asterisks (∗P < 0.05). (D) The increased hematocrit of Mecp2−/y mice was not affected by any treatment.
in WTs, which reached the level of significance in the high-dose
treated group (Figure 2C). The increased hematocrit, which we
reported already earlier forMecp2−/y mice (Fischer et al., 2009),
was still evident in all Mecp2−/y groups; any modulation by
Trolox was not observed (Figure 2D).
Behavioral Testing
Rett patients and Rett mice show complex motor impairment. To
assess whether Trolox may exert any positive effects on motor
coordination, rotarod tests were performed on three consecutive
days (Figure 3A). After habituation (first day), all Mecp2−/y
groups showed a poorer performance on the rotarod on the
second day and only stayed on the treadmill for markedly
( >40%) shorter intervals than the respective WTs. Motor
learning is expected between the second and third day of testing.
Indeed, WT mice regardless of the treatment showed a trend
towards increased running times of ∼20%. In the Mecp2−/y
groups, any improvement of motor learning between the second
and third day was not seen (Figure 3A).
Exploratory behavior and locomotor activity of mice was
determined in an open field arena (Figure 3B). This test
mimics the natural conflict of mice between exploring a novel
environment and avoiding illuminated, open areas. All mice
avoided the center region, rather preferring the periphery and
even more the corners (Figures 3B,C). Marked differences in
the relative times spent within the three zones were not obvious
between Mecp2−/y and WT mice. Mecp2−/y mice treated with
PBS and low-dose Trolox were significantly less active than
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FIGURE 3 | Trolox-treated Mecp2−/y mice still show limited motor skills and reduced activity. (A) In Rotarod tests, the latency to fall was determined on
three consecutive days. All Mecp2−/y mice showed a weaker motor performance than WTs, and Trolox did not affect motor performance in either genotype. (B) Open
field tests rated general locomotor activity and anxiety. The arena was divided in the three virtual zones center, periphery and corner. The sample track represents a
5 min run, and the dimensions of the arena and of the three virtual zones are indicated. (C) The relative times spent in the three zones did not markedly differ among
(Continued)
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FIGURE 3 | Continued
Mecp2−/y and WT groups, nor was it considerably affected by the type of
treatment. (D–F) Mecp2−/y mice treated with PBS or low-dose Trolox traveled
at lower velocities, rested longer and ran shorter distances than the respective
WTs. In high-dose Trolox injected mice, these genotypic differences were not
detectable anymore, as the treatment tended to dampen the activity of WT
mice. (G) Hole-board testing revealed fewer head-dips in Mecp2−/y mice
treated with PBS or low-dose Trolox. In contrast, Mecp2−/y mice receiving
high-dose Trolox showed more frequent head-dips than the other Mecp2−/y
groups, and they did no longer differ from the corresponding WTs. (H) The
resting time was shortened in Mecp2−/y mice receiving high-dose Trolox.
Nevertheless, all Mecp2−/y groups rested significantly longer than the
respective WTs. (I) Y-maze testing did not detect any differences between WT
and Mecp2−/y mice. Asterisks identify genotype-matched differences
(∗P < 0.05), crosshatches indicate differences between the respective
Mecp2−/y and WT groups (#P < 0.05, ##P < 0.01, ###P < 0.001).
WTs, as indicated by their reduced average velocity (Figure 3D),
longer relative resting time (Figure 3E), and shorter total distance
traveled (Figure 3F). Interestingly, these activity parameters did
not significantly differ among high-dose Trolox-treated WT and
Mecp2−/y mice, as WTs tended to become less active under this
treatment (Figures 3D–F).
Environmental exploration of mice was tested by the hole
board.Mecp2−/y mice receiving PBS or low-dose Trolox showed
significantly fewer head-dips than the respective WTs and rested
longer (Figures 3G,H). High-dose Trolox-treatedMecp2−/y mice
became clearly more active than the other Mecp2−/y groups,
showing more head-dips and resting less than PBS-treated
Mecp2−/y mice. Also their head dipping did no longer differ from
high-dose treated WTs (Figure 3G).
For the assessment of spatial working memory, the Y-maze
is considered a useful initial test (Dudchenko, 2004). It can be
performed relatively easily, does not require multiple repeats,
and does not impose high levels of stress or pronounced motor
challenge on the mice. In view of the clear learning/memory
deficits of MeCP2-deficient mice (Pelka et al., 2006) and their
motor impairment, we therefore established this test. Against
expectation, the number of spontaneous alterations did not
differ among the respective WT and Mecp2−/y groups, nor did
genotype-matched comparison indicate any effects of Trolox
(Figure 3I). This suggests that the spatial complexity of only
three arms is not sufficiently challenging to detect clear genotypic
effects.
To evaluate the breathing pattern, unrestrained whole-body
plethysmography was performed. Breathing was clearly
disturbed in PBS-treated Mecp2−/y mice as compared to
WTs (Figure 4A), and Trolox treatment failed to improve the
regularity of breathing in Mecp2−/y mice. All Mecp2−/y groups
still showed a higher incidence of breathing arrests and lower
breathing frequencies than WTs (Figures 4B,C). Accordingly,
the irregularity score, i.e., the variability of respiratory
cycle duration, remained increased in all Mecp2−/y mice
(Figure 4D).
Hypoxia Tolerance
To screen for differences in hypoxia susceptibility, acute
hippocampal tissue slices isolated from treated WT and
Mecp2−/y mice were exposed to transient O2 withdrawal
to trigger an HSD episode, which represents the concerted
network response to severe hypoxia. HSD was recorded as
negative extracellular DC-potential shift, and its characteristic
parameters amplitude (∆V), duration at the half amplitude
level (t1/2), and time to onset (∆t) were analyzed (Figure 5A).
In hippocampal slices of low-dose Trolox-treated Mecp2−/y
mice, the time to HSD onset was significantly increased as
compared to the respectiveWTs and PBS-treatedMecp2−/y mice
(Figure 5B). The amplitude and duration of the DC potential
shift did not differ among genotypes and treatment groups
(Table 2).
Against expectation, the earlier observed increased hypoxia
susceptibility of Mecp2−/y hippocampal slices (Fischer et al.,
2009; Janc andMüller, 2014) was not obvious among PBS-treated
WT and Mecp2−/y mice. To clarify, whether the lack of this
genotypic difference may be due to frequent animal handling
and i.p. injections, seasonal or breeding issues, HSD was
triggered also in slices from untreated (naïve) Mecp2−/y and
WT mice. These controls reproduced the hastened onset of
HSD by ∼28% in slices from Mecp2−/y mice with almost the
identical times to HSD onset (Table 2) reported previously
for naïve Mecp2−/y and WT slices (Janc and Müller, 2014;
Table 3).
Synaptic Function and Plasticity
Synaptic function and plasticity were assessed in acute
hippocampal tissue slices by recording fEPSPs. Basal synaptic
function, as judged on normalized i/o curves, did not noticeably
differ between PBS-treated WT andMecp2−/y mice (Figure 6A).
The pronounced hyperexcitability observed earlier in slices
of naïve Mecp2−/y mice (Janc and Müller, 2014), was not
present among the PBS-injected groups. Neither did Trolox
treatment induce any significant effects on basal synaptic
function (Figure 6A). Trolox treatedWTmice showed, however,
a trend towards reduced fEPSP amplitudes.
Synaptic plasticity was rated upon high-frequency
stimulation, which mediated a robust short-term potentiation
(STP) and LTP of fEPSPs in all Mecp2−/y and WT groups,
regardless of treatment (Figures 6B,C). The amount of STP,
determined right after the third stimulus train, was significantly
more pronounced in low-dose Trolox-treated Mecp2−/y mice
than in the respective WTs and in Mecp2−/y mice receiving
PBS or high Trolox (Figure 6D). Other differences between
genotypes and/or treatment groups were not detected. The
degree of LTP (determined at 50–60 min upon train stimulation)
did not differ significantly among the various groups, but the
final level of LTP reached, tended to be higher in low-dose
Trolox-treated than in PBS injectedMecp2−/y mice (Figure 6D).
Mitochondrial Metabolism and Function
RTT is accompanied by mitochondrial alterations. To
assess whether Trolox-treatment may mediate any effects
on mitochondrial metabolism, we monitored FAD/NADH
autofluorescence as well as Rh123 fluorescence in acute
hippocampal tissue slices of the treated mice. In correspondence
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FIGURE 4 | Irregular breathing of Mecp2−/y mice persists upon Trolox treatment. (A) Breathing pattern typically seen during whole-body plethysmography in
WT and Mecp2−/y mice. The recordings were obtained from PBS-treated mice; note the frequent breathing arrests in the Mecp2−/y mouse (arrows). (B) In all
Mecp2−/y groups, breathing arrests were far more frequent than in WTs. Plotted is the total number of breathing arrests exceeding 750 ms within a time period of
3 min. (C) Averaged breathing frequencies were significantly lower in all Mecp2−/y mice than in WTs. (D) Severe breathing disturbances in Mecp2−/y mice are
evident as a noticeably increased irregularity score, which persisted despite Trolox treatment. Differences between the respective Mecp2−/y and WT groups are
indicated by crosshatches (###P < 0.001).
to the electrophysiological recordings, these imaging
experiments were performed in CA1 st. radiatum. The basal
ratio of FAD/NADH autofluorescence did not differ among
PBS and high-dose Trolox treated Mecp2−/y and WT mice;
but it was slightly decreased in low-dose Trolox-treated WTs
(Figure 7A). Pharmacological inhibition of mitochondrial
respiration by low (100 µM) and high (1 mM) doses of CN−
provoked the expected decreases in FAD/NADH ratio, whose
magnitudes were similar among treatment groups and genotypes
(Figure 7A).
Mitochondrial polarization and anoxia vulnerability
were assessed in Rh123-loaded slices, by evoking maximum
depolarization with the uncoupler FCCP (5 µM, 5 min) and
blocking mitochondrial respiration with CN− (100 µM, 2 min),
respectively. The maximum mitochondrial depolarization,
indicated by a massive increase in Rh123 fluorescence, did not
differ among genotypes and treatment groups (Figure 7B).
Neither did CN−-mediated inhibition of respiration evoke any
different mitochondrial depolarizations (Figure 7C). It therefore
can be concluded that Trolox treatment—even when applied
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FIGURE 5 | Low-dose Trolox increases the hypoxia tolerance of Mecp2−/y hippocampus. (A) Negative extracellular DC potential shift associated with the
occurrence of hypoxia-induced spreading depression (HSD). Recording was performed in CA1 st. radiatum of an acute slice of a PBS-treated Mecp2−/y mouse.
The characteristic parameters of the DC potential shift (∆t, time to onset; ∆V, amplitude; t1/2, duration) are defined. (B) Low-dose Trolox treatment postponed HSD
onset in Mecp2−/y slices as compared to the respective WTs and PBS-treated Mecp2−/y mice. Asterisks identify genotype-matched differences (∗P < 0.05),
crosshatches indicate differences between the respective Mecp2−/y and WT groups (###P < 0.001).
systemically over a longer period—does not generally interfere
with mitochondrial metabolism and function.
Lipid Peroxidation and Protein
Carbonylation
The redox alterations associated with RTT were reported to
culminate in oxidative damage in the brains of Rett mice (De
Felice et al., 2014). Therefore, we determined the extent of
lipid peroxidation and protein carbonylation in brain tissue of
the treated mice (∼PD50), to rate the antioxidative capacity
of Trolox. These tests were performed on neocortex, as the
hippocampi had already been used for the previously described
FAD/NADH and Rh123 imaging experiments. First, we verified
the feasibility of the chosen assays, and incubated neocortical
tissue samples with the oxidant tert-butyl hydroperoxide (TBHP;
500 µM, 10 min) to induce oxidative damage. As compared to
control tissue, TBHP increased lipid peroxidation and protein
TABLE 2 | Summary of the characteristic hypoxia-induced spreading depression (HSD) parameters for the different wild type (WT) and Mecp2−/y groups.
Treatment WT Mecp2 −/y
Time to onset [s] PBS only 144.2 ± 32.9 (n = 27) 140.7 ± 26.8 (n = 29)
10 mg/kg Trolox 127.8 ± 35.3 (n = 28) 168.7 ± 57.0 (n = 28)
40 mg/kg Trolox 151.5 ± 45.8 (n = 26) 150.4 ± 46.4 (n = 21)
Naïve slices 160.0 ± 39.3 (n = 4) 116.0 ± 19.3 (n = 4)
Amplitude [mV] PBS only −14.6 ± 2.8 −15.7 ± 3.5
10 mg/kg Trolox −14.7 ± 3.9 −14.4 ± 3.3
40 mg/kg Trolox −14.5 ± 2.5 −14.1 ± 4.0
naïve slices −15.9 ± 3.3 −18.4 ± 2.7
Duration [s] PBS only 69.5 ± 12.7 65.0 ± 13.6
10 mg/kg Trolox 63.4 ± 13.1 62.6 ± 10.3
40 mg/kg Trolox 70.6 ± 20.0 67.4 ± 11.1
Naïve slices 74.1 ± 9.7 63.1 ± 3.5
The number of slices analyzed is reported. The group of naïve slices represents control tissue isolated from otherwise untreated and non-handled mice.
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TABLE 3 | Genotypic differences among WT and Mecp2-/y mice that either underwent PBS (placebo only) treatment or were not injected and handled
frequently (naïve mice).
PBS-treated mice Naïve mice
Parameter WT Mecp2-/y WT Mecp2-/y
Hematocrit 43.7 ± 2.4% (n = 20) 48.2 ± 3.5% (n = 19)### 44.1 ± 1.4% (n = 7) 49.8 ± 2.3% (n = 8)###
CA1 pyramidal neuron size 137 ± 26 µm2 (n = 60) 125 ± 25 µm2 (n = 90)## 152 ± 29 µm2 (n = 300) 137 ± 26 µm2 (n = 300)###
FAD/NADH ratio no genotypic difference Mecp2−/y 10.9% higher than WT
(WT n = 20; Mecp2−/y n = 23) (WT n = 19; Mecp2−/y n = 17)#
Rh123 response to uncoupling 73 ± 18% (n = 13) 80 ± 25% (n = 15) 90 ± 26% (n = 13) 70 ± 11% (n = 13)#
HSD onset (∆t) 144 ± 33 s (n = 27) 141 ± 27 s (n = 29) 147 ± 16 s (n = 37) 106 ± 18 s (n = 32)###
Normalized fEPSPs (150 µA) 422 ± 143% (n = 20) 417 ± 171% (n = 20) 338 ± 153% (n = 52) 473 ± 202% (n = 37)###
STP 176 ± 42% (n = 14) 156 ± 51% (n = 11) 238 ± 62% (n = 12) 159 ± 38% (n = 11)##
LTP 157 ± 42% (n = 14) 156 ± 32% (n = 11) 179 ± 31% (n = 12) 143 ± 19% (n = 11)##
The listed absolute values of naïve mice are reference data obtained in our earlier studies (Fischer et al., 2009; Großer et al., 2012; Janc and Müller, 2014). FAD/NADH
ratios in naïve and PBS-treated mice were recorded with different optical components. Therefore, only relative data but no absolute values can be compared. Crosshatches
indicate genotypic differences among WT and Mecp2−/y mice (#P < 0.05, ##P < 0.01, ###P < 0.001). Shaded cells identify those parameters, differing among naïve mice,
but not among PBS-treated WT and Mecp2−/y mice.
carbonyl content by 59.4 ± 8.2% and 79.7 ± 16.1% (each n = 3),
respectively, confirming that both assays are functional.
Comparing neocortical samples from PBS-treated WT and
Mecp2−/y mice, did not reveal any genotypic differences
in lipid peroxidation (Figure 8A). In Mecp2−/y mice
treated with high-dose Trolox, however, the degree of lipid
peroxidation was significantly dampened as compared to
PBS- and low-dose Trolox injected Mecp2−/y mice and
high-dose Trolox treated WT mice (Figure 8A). In WTs,
high-dose Trolox just showed a tendency to decrease lipid
peroxidation. Protein carbonyl content was increased in
PBS-treated Mecp2−/y mice as compared to the corresponding
WTs, whereas in low- and high-dose Trolox treated Mecp2−/y
mice this genotypic difference was no longer detectable
(Figure 8B). Accordingly, the degree of oxidative damage
in brain tissue can be ameliorated at least partly by Trolox
treatment.
Morphological Analyses
MeCP2-deficiency is associated with decreased brain size,
thinning of neocortical layers and smaller neurons (Belichenko
et al., 2008; Fischer et al., 2009). To screen for changes in these
parameters, we performed morphological analyses on perfusion-
fixed brains of the treated mice. Nissl staining of thin coronal
sections (30 µm) revealed the expected reduction in total brain
size in Mecp2−/y mice (Figure 9A). As referred to PBS-treated
WTs, the total hemisphere size in the respective Mecp2−/y
group was smaller by an average of 9.4%, the hippocampal
formation was reduced by 7.0% and neocortical layers—as
analyzed here for the primary somatosensory cortex (trunk
region)—were thinned by 9.1% (Figures 9B–D). The soma
of CA1 pyramidal neurons was also smaller in PBS-treated
MeCP2-deficient mice by an average of 8.7% than in the
respective WTs (Figure 9E). Systemic Trolox treatment did
not mediate any effects on these morphological parameters
in WT and Mecp2−/y mice, nor did it reverse the genotypic
differences.
DISCUSSION
Our earlier in vitro tests revealed promising effects of Trolox
on hippocampal network function in symptomatic Mecp2−/y
mice (Janc and Müller, 2014). As the next logical step
we therefore assessed, whether in vivo treatment with this
free-radical scavenger would be equally efficient and improve
the physical constitution of Mecp2−/y mice or slow down
disease progression. Chronic treatment and frequent injections
were largely well-tolerated over the entire ∼6 weeks. Only a
small number of mice (3 WTs, 14 Mecp2−/y) died or had to
be euthanized before the end of treatment. The survival rate
of all treated Mecp2−/y mice was 86% at PD47–50, and this
average does not noticeably differ from that of naïve, untreated
animals in our Rett mouse colony or the observations of others
(Guy et al., 2001). Taking a closer look at the specific survival
rates of the different treatment groups (Table 1) indicates,
however, that the mice which died or had to be euthanized
even included three WTs and that they all (with the exception
of one Mecp2−/y mouse) had received Trolox and not placebo.
It therefore seems that even though the administered doses
of Trolox were far below the LD50 lethal dose for mice (i.p.
injection 1700 mg/kg see http://www.drugfuture.com/toxic/q28-
q963.html), some adverse effects of systemic Trolox treatment
cannot be excluded.
For example, WT mice receiving high-dose Trolox
showed lowered blood glucose levels, and a trend towards
decreased motor activity as well as reduced environmental
exploration, whereas low-dose Trolox treated WTs had lower
FAD/NADH baseline ratios and a tendency to decreased
fEPSP amplitudes. The very underlying causes are unclear,
but nevertheless this observation emphasizes the importance
of proper antioxidant dosing and optimized titration of redox
conditions. Without question, cellular viability suffers from
an increased oxidant load, but in view of the numerous
functions controlled by redox conditions, also an ‘‘over-
buffering’’, i.e., too reducing conditions may be equally
damaging.
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FIGURE 6 | Improved synaptic plasticity in Mecp2-/y mice after low-dose Trolox treatment. (A) Input/output (i/o) curves of all treatment groups recorded in
acute hippocampal slices. Plotted field excitatory postsynaptic potential (fEPSP) amplitudes are normalized to the fiber volley, representing the averages of
20–27 slices. Significant genotypic differences or treatment effects on neuronal excitability were not found, but Trolox treated WT mice tended to show somewhat
reduced fEPSP amplitudes. (B) Sample fEPSPs of PBS-treated WT mice under baseline conditions, immediately after high-frequency stimulation (short-term
potentiation, STP), and 1 h after inducing long-term potentiation (LTP). Stimulation artifacts are truncated. (C) STP was improved and the degree of LTP tended to
increase in low-dose Trolox-treated Mecp2−/y mice as compared to the respective WT group. For clarity, error bars are omitted. Synaptic potentiation (STP, LTP) was
induced by three consecutive 100 Hz stimulation trains (arrow marks), lasting 1 s each. (D) Comparing STP and LTP for the different groups shows that STP is
significantly improved only in low-dose Trolox-treated Mecp2−/y mice. Further differences among genotypes and/or treatment groups were not found. Asterisks
identify genotype-matched differences (∗P < 0.05), crosshatches indicate differences between the respective Mecp2−/y and WT groups (#P < 0.05).
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FIGURE 7 | Systemic Trolox treatment does not in general interfere with mitochondrial function. (A) Recording the ratio of FAD/NADH autofluorescence in
hippocampal slices did not identify consistent differences in basal mitochondrial respiration (artificial cerebrospinal fluid, ACSF) and in the responses to CN−-induced
anoxia among Mecp2−/y and WT mice or the different treatment groups. Note however, that low-dose treated WTs showed lower FAD/NADH baseline levels than
the corresponding Mecp2−/y group (##P < 0.01). Error bars are plotted in one direction only (WT down, Mecp2−/y up), and the number of slices analyzed is
indicated. (B) The mitochondrial membrane potential responses to FCCP-induced uncoupling, measured as an increase in rhodamine 123 (Rh123) fluorescence, did
not differ among the various groups. Therefore, major differences in mitochondrial polarization can be ruled out. (C) Chemical anoxia, induced by 100 µM CN−,
elicited a pronounced mitochondrial depolarization, plotted here in reference (normalized) to the maximum FCCP-induced depolarization. These anoxia-mediated
increases in Rh123 fluorescence did not differ among genotypes or treatment groups, suggesting similar mitochondrial vulnerabilities to mitochondrial challenge.
This preclinical trial is part of a long-lasting research line,
and we have reference data on some of the parameters assessed,
which were recorded earlier also from naïve mice. Comparing
the data sets shows that some of the genotypic differences
seen in naïve mice were either not present or less pronounced
among PBS-treated WT andMecp2−/y mice (Table 3). In several
parametersWTs became worse, which dampened the phenotypic
differences to Mecp2−/y mice. An obvious cause may be the
frequent injections and animal handling, which might have
resulted in adverse stress. During study design, we chose i.p.
injections, as they ensure a highly reliable drug delivery and are
applicable also to neonates. Osmotic mini pumps are not feasible
for mice at the early postnatal age and oral feeding (via drinking
water or chow) could only start after weaning, i.e., not before
PD20, unless the (foster) mothers are treated as well.
There are of course further reasons which may explain the
reduced efficacy of Trolox in vivo as compared to in vitro.
Even though Trolox shows a relatively high blood-brain barrier
transferability (Wada et al., 2016), it reaches an antioxidative
effect of only ∼65% of that observed in blood. Thus, it may
not have reached sufficiently high doses to reverse all of
these symptoms arising as a consequence of redox-imbalance
and oxidative stress. Since higher doses of Trolox cannot be
achieved without the use of additional solvents, shorter intervals
and/or different routes of administration may be preferable
for future trials. Furthermore, recent studies have pointed
out that combinations of antioxidants—even applied at lower
doses—may potentiate each others efficacy, and that this strategy
may be more promising than just increasing the dose of a
single compound (Tarnopolsky, 2008; López-Erauskin et al.,
2011).
General Physical Appearance and Blood
Parameters
The detailed assessment of body weights and BMI revealed
that Trolox treatment did not ameliorate the reduced growth
of Mecp2−/y mice. Once separated from their foster mothers
and required to feed on their own, all Mecp2−/y groups
gained less weight than their WT littermates, as was reported
earlier also for non-treated Mecp2−/y mice (Guy et al.,
2001).
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FIGURE 8 | Trolox dampens oxidative tissue damage in Mecp2−/y neocortex. (A) The malondialdehyde (MDA) level, a marker for lipid peroxidation, did not
differ among PBS- or low-dose Trolox-treated WT and Mecp2−/y mice. Yet, Mecp2−/y mice receiving high-dose Trolox, showed significantly lower MDA levels than
the PBS- and low-dose Trolox treated Mecp2−/y group and high-dose Trolox treated WTs. (B) Protein carbonylation, an indicator for oxidative damage of proteins,
was higher in PBS-treated Mecp2−/y mice than in WTs. Among the Trolox-treated groups, this genotypic difference was no longer present. Asterisks identify
genotype-matched differences (∗∗∗P < 0.001), crosshatches indicate differences between the respective Mecp2−/y and WT groups (#P < 0.05).
Weaning marks a switch in metabolism from milk (high
fat diet) to mouse chow (carbohydrate rich diet; Ferré et al.,
1986), and this transition seems problematic in Mecp2−/y mice.
Loss of MeCP2 function increases insulin levels, decreases
insulin signaling and results in a dissociation of insulin
levels and their appropriate metabolic effects on glucose
regulation (Pitcher et al., 2013; Krishnan et al., 2015). Also
in Rett patients, increased glucose utilization indicates altered
glucose regulation and/or metabolism (Villemagne et al., 2002).
We found ∼29% lower blood glucose levels in PBS-treated
Mecp2−/y mice than in WTs. This difference was abolished in
Mecp2−/y mice receiving high or low Trolox doses, indicating
that chronic Trolox treatment rescued the altered glucose
regulation/metabolism.
Interestingly, it was shown in rats that glucose-mediated
production of mitochondrial ROS is mandatory for insulin
secretion; higher mitochondrial ROS levels increased insulin
secretion, whereas antioxidants decreased it (Leloup et al.,
2009). Thus the lower glucose levels observed in placebo
treated Mecp2−/y mice may at least in part be a consequence
of the systemic oxidative stress in these mice, which is then
antagonized by Trolox. In contrast inWTmice, high-dose Trolox
slightly lowered blood glucose levels by an as yet unidentified
mechanism. For male C57BL6 mice (PD 56–70), the vendor
specifies a blood glucose content of 13.7 ± 3.4 mM (n = 114; see
http://www.criver.com/files/pdfs/rms/c57bl6/rm_rm_d_c57bl6n
_mouse.aspx). High-dose Trolox treated WTs showed glucose
levels of 12.1 ± 2.1 mM (n = 23), which are well within this
range. As neither the growth curves of high-dose Trolox treated
WT mice, nor any other of their behavioral parameters showed
a significant decline, adverse systemic consequences of these
moderate blood glucose changes seem unlikely.
The hematocrit was not affected by Trolox, and remained
increased in all Mecp2−/y groups. As the high hematocrit
represents an adaptive response of Mecp2−/y mice to irregular
breathing and the associated intermittent systemic hypoxia
(Stettner et al., 2008; Fischer et al., 2009), this suggests
that Mecp2−/y mice, despite chronic Trolox treatment, still
suffered from intermittent systemic hypoxia. The unchanged
breathing irregularities detected in all Mecp2−/y groups during
plethysmography support this notion.
Behavioral Testing and Plethysmography
Motor problems and insufficient motor skills are evident in
various MeCP2-mutant mice (Guy et al., 2001; Shahbazian et al.,
2002; Moretti et al., 2005; Wegener et al., 2014). Compared
to WTs, the treated Mecp2−/y mice failed markedly earlier
on the rotarod, and their impaired motor function was not
ameliorated by Trolox. The poor rotarod performance likely
arises from an insufficient motor coordination, as is suggested
by the pronounced hind limb clasping in symptomaticMecp2−/y
mice (Guy et al., 2001). General muscle weakness is a less
likely cause. We found most Mecp2−/y mice being able to climb
around in their cages, and others confirmed normal muscle
strength ofMecp2−/y mice in wire suspension tests (Santos et al.,
2007).
Mecp2−/y mice are also less active (Guy et al., 2001), which
in part may be due to their motor deficits. They traveled
shorter distances than WTs, which in the open field and hole
board tests was accompanied by a decline in mean velocity
and prolonged resting times. Marked genotypic differences
in the relative times spent in the defined areas were not
found, but low-dose Trolox-treated Mecp2−/y mice stayed
slightly more in the periphery and less in the corners than
the respective WTs. Environmental exploration in the hole
board was also less pronounced in Mecp2−/y mice. Yet, the
number of head-dips was increased in high-dose Trolox-treated
Mecp2−/y mice as compared to the other Mecp2−/y groups,
and they did no longer differ from high-dose Trolox-treated
WTs. This was paralleled by a shortened mean resting time
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FIGURE 9 | Microcephaly inMecp2−/y mice is not ameliorated by Trolox treatment. (A) Nissl staining of sections (30 µm) from perfusion-fixed brains revealed
the expected differences in brain size among WT and Mecp2−/y mice. (B,C) The reduced brain size of Mecp2−/y mice affects both, total hemispherical as well as
hippocampal areas, and it is not rescued by Trolox. Bar shading and patterns are identical for all panels, the number of slices analyzed also applies to panel (D).
(D) Cortical layer thickness was assessed in the primary somatosensory cortex as depicted here (arrow mark) in a slice of a PBS-treated WT mouse. Independent of
the treatment received, neocortical thinning was still present in all Mecp2−/y mice. (E) The reduced size of MeCP2-deficient CA1 pyramidal neurons, plotted here as
soma area, persists upon Trolox treatment. The number of cells analyzed is indicated below each bar. The sample image shows a CA1 st. pyramidale segment of a
PBS-treated WT mouse. Crosshatches indicate differences between the respective Mecp2−/y and WT groups (##P < 0.01, ###P < 0.001).
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of the respective Mecp2−/y mice. Accordingly, environmental
exploration in Mecp2−/y mice slightly improved upon Trolox
treatment.
One of the most prominent symptoms in RTT is erratic
breathing (Julu et al., 2001; Weese-Mayer et al., 2006; Stettner
et al., 2008; Katz et al., 2009). Each episode of irregular
breathing evokes a drop in arterial O2 saturation, which is
restored only after normal ventilation resumes. Such intermittent
systemic hypoxia may provoke damage and/or induce redox
stress in highly vulnerable neuronal tissue. Also the regulation
of breathing itself might be affected. H2O2-evoked oxidative
stress modulates the in vitro breathing pattern generated in
the isolated medullary pre-Bötzinger Complex of neonatal
WT mice: Biphasic responses were reported, consisting of an
initial depression followed by augmented respiratory activity
(Garcia et al., 2011). Therefore, we also assessed whether
Trolox may improve breathing. As expected, Mecp2−/y mice
showed highly irregular breathing patterns. High- or low-dose
Trolox did not improve the regularity of breathing, and the
number and duration of apneas did not decrease. Yet, a
further deterioration of breathing was not observed either.
It should be mentioned though that the individual Mecp2−/y
mice varied greatly; some displayed only mild breathing
disturbances with just 1–2 apneas during the evaluated 3 min
interval, whereas others showed up to 49 apneas exceeding
750 ms.
Hypoxia Susceptibility and Synaptic
Function
In contrast to our earlier studies on naïve mice (Fischer
et al., 2009; Janc and Müller, 2014), PBS-treated WT and
Mecp2−/y mice did not differ in their hypoxia susceptibility
assessed as time to HSD onset. Nevertheless, treatment with
low-dose Trolox increased the hypoxia tolerance of Mecp2−/y
mice as compared to the respective WT and the PBS-treated
Mecp2−/y group. This effect was not seen with high-dose
Trolox, emphasizing the importance of well-adjusted cellular
redox balance and careful antioxidant dosing. In view of
the irregular breathing and intermittent hypoxia, the Trolox-
mediated increase in hypoxia tolerance is clearly of merit, as
it may prevent additional complications especially in highly
anoxia-vulnerable neuronal networks such as the hippocampus
and cortex.
Synaptic plasticity is impaired in Mecp2-mutant mice (Asaka
et al., 2006; Moretti et al., 2006; Fischer et al., 2009; Janc
and Müller, 2014). Yet, the differences among PBS-treated
Mecp2−/y and WT mice were less evident than in naïve mice
(Janc and Müller, 2014). As suggested by the normalized
fEPSP amplitudes recorded in CA1 st. radiatum (Table 3),
this seems to result from PBS-treated WTs showing a higher
degree of neuronal excitability than naïve WT mice. This
variability of genotypic differences in synaptic plasticity may
be explained by earlier reports identifying stress and stress-
hormones as a cause for impaired hippocampal LTP (Kim
and Yoon, 1998; Kim and Diamond, 2002). Repeated i.p.
injections for several weeks could represent a chronic stressor
(Ryabinin et al., 1999) which induces stress hormone release
and dampens LTP in slices of frequently handled/injected
WT mice. In Mecp2−/y mice, LTP is already impaired to
a degree that it may not have responded to any additional
stress.
Nevertheless, in vivo Trolox treatment mediated some
positive effects on synaptic plasticity. Low-dose Trolox-treated
Mecp2−/y mice showed a significantly improved STP as
compared to the respective WTs and the other Mecp2−/y
groups. The final amount of LTP also tended to increase,
but did not reach the level of significance. High-dose Trolox
treatment failed to improve synaptic plasticity in Mecp2−/y
or WT mice. This may result from a probably too high
concentration mediating adverse effects. As a certain ROS level
is necessary for signal transduction cascades during normal
physiological processes (Serrano and Klann, 2004), optimum
synaptic plasticity can be achieved in a well-balanced redox
environment only. Accordingly, superoxide scavenging and
overexpression of superoxide dismutase 3 impair hippocampal
LTP (Klann et al., 1998; Thiels et al., 2000). Along this line,
high-dose Trolox may have shifted hippocampal redox balance
beyond the optimum. Similar effects we found earlier in naïve
mice, in which Trolox rescued STP and LTP in Mecp2−/y
hippocampal slices, but dampened it in WTs (Janc and Müller,
2014).
Mitochondrial Metabolism and Function
Trolox did not mediate any consistent changes in mitochondrial
metabolism or polarization. A slight decrease of the FAD/NADH
baseline ratio was found in low-dose Trolox treated WTs, but
this was not accompanied by any changes in mitochondrial
polarization, estimated here as Rh123 fluorescence. Hence,
general negative side effects of this compound on mitochondrial
function can be excluded. In contrast to our earlier studies
on naïve mice (Großer et al., 2012; Janc and Müller,
2014), PBS injected/handled WT and Mecp2−/y did no
longer differ in their hippocampal FAD/NADH ratios and
Rh123 responses (Table 3). Again, the stress associated
with the frequent i.p. injections, might have affected
mitochondrial metabolism, thereby diminishing the genotypic
differences. Most primary mediators of stress responses exert
numerous effects on mitochondrial metabolism and ROS
generation and may even induce apoptosis (Manoli et al.,
2007).
Lipid Peroxidation and Protein
Carbonylation
RTT is closely linked to oxidative stress and redox imbalance
(Sierra et al., 2001; De Felice et al., 2011, 2012b; Großer
et al., 2012; Müller and Can, 2014). Unclear is, however, which
particular brain regions are affected and whether the oxidative
damage mainly targets proteins, lipids or both. Earlier studies
on whole brains of various Rett mouse models indicated that
in particular lipids are subject to oxidative damage, whereas
protein damage is not detectable in each model (De Felice
et al., 2014). Our comparison of neocortical tissue of PBS-treated
Frontiers in Cellular Neuroscience | www.frontiersin.org 16 November 2016 | Volume 10 | Article 266
Janc et al. Systemic Trolox Treatment in Rett Syndrome
WT and Mecp2−/y mice did not reveal obviously different
levels of lipid peroxidation, but high-dose Trolox decreased
the extent of lipid peroxidation in Mecp2−/y neocortex below
WT levels. Furthermore, the increased protein carbonyl content
detected in PBS treated Mecp2−/y mice, was no longer evident
upon Trolox treatment. This confirms that systemic Trolox
administration is capable of ameliorating oxidative brain tissue
damage. However, it also should be noted here that the sensitivity
range of these assays may not be ideal to detect reliably also
more subtle changes in protein and lipid oxidation. We verified
both assays by provoking oxidative tissue damage via direct
oxidant (TBHP) treatment. This resulted in a clear peroxidation
of lipids and carbonylation of proteins in neocortical samples,
but it also revealed that despite direct oxidant stress only marked
but not massive changes in spectrophotometric readout were
obtained.
Merits of Antioxidant and Free-Radical
Scavenger Treatment in RTT
Various earlier studies verified that antioxidants and free-radical
scavengers ameliorate certain aspects of the complex clinical
appearance of RTT (Chapleau et al., 2013). In female Rett
mice, alterations in vascular endothelium were reversed by
administration of curcumin, an anti-inflammatory compound
which also mediates antioxidative effects (Panighini et al.,
2013). In Rett patients, ω-3 PUFA-supplementation led to an
improvement ofmotor function, non-verbal communication and
breathing regularity (De Felice et al., 2012a; Maffei et al., 2014).
Ultimate proof for a pathogenic role of oxidative alterations in
RTT is the brain-specific reactivation of the Mecp2 gene, which
resulted in a clear phenotypic improvement in concert with
a normalization of various oxidative stress markers (De Felice
et al., 2014).
As vitamin E levels are decreased in blood serum of Rett
patients (Formichi et al., 1998) and as this vitamin as well as
its derivatives act as chain-breaking antioxidants, which prevent
the propagation of free radicals in membranes and plasma
lipoproteins (Traber and Stevens, 2011; Alberto et al., 2013),
these compounds appear especially promising. Applied in vivo
by oral uptake or i.p. injection, Trolox ameliorates ischemia-
induced hippocampal cell loss and 3-NPA-mediated striatal
lesions (Gupta and Sharma, 2006; Al Mutairy et al., 2010) as
well as oxidative-stress related retinal damage (Dorfman et al.,
2006). Our previous in vitro tests confirmed the efficacy of
Trolox also in a Rett mouse model, in which it improved
synaptic function as well as hypoxia tolerance and opposed
neuronal hyperexcitability inMecp2−/y hippocampal slices (Janc
and Müller, 2014).
In the present study, the systemic administration of Trolox
improved some of the tested parameters as well. Yet, this
in vivo Trolox treatment did not noticeably change the most
characteristic Rett symptoms. Obvious signs that the disease
progression was slowed down in Mecp2−/y mice were not
obtained either. It has to be considered though that these male
Rett mice are very severely affected. Therefore, to understand
completely the merits of systemic Trolox administration, it needs
to be assessed in future trials, how efficient this treatment
would be in heterozygous female Rett mice. They represent
the conditions of a cellular MeCP2 mosaicism, truthfully
reflecting the genetic conditions of the female patients. As
disease progression and symptom severity are milder in female
Rett (Mecp2+/−) mice, this will require, however, prolonged
treatment durations of several months or even over a year. This
certainly cannot be achieved by i.p. injections and the associated
stress, as we learned in this present study.
In conclusion, this detailed in vivo study confirms some
pharmacotherapeutic merit of systemically applied antioxidants
in MeCP2-deficient brains. Unfortunately, frequent animal
handling and repeated injections apparently modulated the
phenotypic appearance of mice and diminished the genotype-
related differences of numerous parameters. Therefore, the route
of drug administration and the frequent mouse handling are
critical issues in study design, which need to be further optimized
in future trials. Also, as Trolox ameliorated only a few of
the multiple complex Rett symptoms, one may consider its
use as adjuvant, i.e., its combination with other compounds
improving different symptoms, in order to complement the
spectrum of effects. For example, respiration, which was not
improved by Trolox was shown earlier to be normalized by
norepinephrine uptake blockers, GABA uptake inhibitors, and
serotonin 1a receptor agonists (Zanella et al., 2008; Abdala
et al., 2010) or the antidepressant mirtazapine which furthermore
prevented cortical atrophy (Bittolo et al., 2016). In view of
the complex phenotype of RTT, such combination therapies,
designed to the particular needs of each individual patient are
probably the most promising but also the most challenging
strategy.
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